These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36655340)

  • 21. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
    Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
    Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
    Ren H; Berry S; Malkin SJP; Hunt B; Bain S
    BMJ Open; 2023 Sep; 13(9):e070473. PubMed ID: 37775297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
    Niu S; Alkhuzam KA; Guan D; Jiao T; Shi L; Fonseca V; Laiteerapong N; Ali MK; Schatz DA; Guo J; Shao H
    Diabetes Obes Metab; 2024 Feb; 26(2):463-472. PubMed ID: 37867175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
    Tall Bull S; Nuffer W; Trujillo JM
    J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
    Evans M; Chubb B; Malkin SJP; Berry S; Lawson J; Hunt B
    Diabetes Obes Metab; 2023 Feb; 25(2):491-500. PubMed ID: 36251282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
    Viljoen A; Pantalone KM; Galindo RJ; Cui X; Huh R; Hemmingway A; Fernández Landó L; Patel H
    Diabetes Ther; 2023 May; 14(5):925-936. PubMed ID: 37000390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Boye KS; Thieu VT; Sapin H; Lee CJ; Landó LF; Brown K; Bray R; Wiese RJ; Patel H; Rodríguez Á; Yu M
    Diabetes Ther; 2023 Nov; 14(11):1833-1852. PubMed ID: 37526908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
    Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
    Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
    Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B
    Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
    Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
    Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
    Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
    Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ; Radermecker RP; Paquot N
    Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
    Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
    Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
    Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.